NBIX Faces Q1 Print with Bears Building Ahead of Crenessity Verdict
Neurocrine Biosciences heads into its May 1 Q1 results with short sellers meaningfully more aggressive than they were just a month ago — and options traders turning cautious on the day before the release. The short…